News · Harm Reduction · ZYN
FDA Approves ZYN as Lower Risk Than Cigarettes —
What It Means for Canadians
What the FDA Actually Decided
The FDA issued Modified Risk Tobacco Product (MRTP) granted orders to Swedish Match USA — the Philip Morris International subsidiary that makes ZYN — for 20 specific nicotine pouch products. These products were already authorized for legal sale in the US since January 2025 following a rigorous Premarket Tobacco Product Application (PMTA) review. Today’s decision goes further.
What changed today is that Swedish Match can now actively market ZYN products with a specific, FDA-authorized health claim that no nicotine pouch has ever been permitted to make before. The exact claim, word for word:
“Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”
This is a landmark decision. It’s the first time the FDA has granted a Modified Risk designation to any nicotine pouch product, and it represents years of scientific review, epidemiological data, and regulatory process. The FDA based its decision on Swedish Match’s application data, consumer perception studies, youth risk assessment, and recommendations from a January 2026 Tobacco Products Scientific Advisory Committee meeting.
Which ZYN Products Are Covered?
The MRTP authorization applies to 20 specific products — ten flavours, each in 3mg and 6mg strength. The flavours included are:
ZYN Chill (3mg & 6mg)
ZYN Cinnamon (3mg & 6mg)
ZYN Citrus (3mg & 6mg)
ZYN Coffee (3mg & 6mg)
ZYN Cool Mint (3mg & 6mg)
ZYN Menthol (3mg & 6mg)
ZYN Peppermint (3mg & 6mg)
ZYN Smooth (3mg & 6mg)
ZYN Spearmint (3mg & 6mg)
ZYN Wintergreen (3mg & 6mg)
What Does Modified Risk Actually Mean?
Modified Risk Tobacco Product is a specific regulatory category under the US Tobacco Control Act. It doesn’t mean “safe” — the FDA is explicit that there is no safe tobacco product. What it means is that, following extensive scientific review, the FDA concluded that the specific risk reduction claim Swedish Match applied for is scientifically accurate, that adult consumers understand it correctly, and that marketing the products with that claim would benefit the population as a whole.
Key distinction: MRTP authorization is not the same as FDA approval in the pharmaceutical sense. It means a specific marketing claim has been scientifically validated. The FDA is not saying ZYN is safe, harmless, or recommended. It is saying that for adult smokers who switch completely from cigarettes to ZYN, the science supports a meaningful reduction in risk for specific diseases.
The decision comes with conditions. Swedish Match is required to conduct ongoing postmarket surveillance and studies assessing user behaviour and understanding of the risk claim. The orders expire in five years, after which Swedish Match can apply to renew them. If the FDA determines at any point that the marketing is harming the population — for example, by significantly increasing youth uptake — it can withdraw the authorization.
What This Means for Canadian ZYN Users
This is where Canadian smokers and pouch users should pay attention — and where it’s important to be precise about what the FDA’s decision does and doesn’t change north of the border.
- Swedish Match can legally advertise ZYN with the lower-risk claim
- The 20 authorized products can now carry modified risk messaging on packaging
- Consumers can reference FDA authorization when making switching decisions
- It signals mainstream regulatory acceptance of nicotine pouches as a harm reduction tool
- This is a US FDA ruling — Health Canada has not issued equivalent authorization
- Canadian retailers cannot make the same modified risk claims on products or in advertising
- ZYN remains legal to purchase and use in Canada for adults 19+
- The underlying science referenced by the FDA applies globally — the products are the same
- Canadian regulatory framework will likely follow the direction of this decision over time
The practical takeaway for Canadians: the harm reduction context — that switching completely from cigarettes to nicotine pouches eliminates exposure to combustion byproducts responsible for the majority of smoking-related disease — is not a US-only phenomenon. It’s biology.
Why This Matters for Smokers Considering the Switch
For years, nicotine pouches have existed in a grey zone — legal, growing rapidly, but without official regulatory validation of the harm reduction argument. Today’s FDA decision changes that, at least in the United States. It gives smokers who are weighing their options a concrete data point: a major regulatory agency, after years of scientific review, concluded that switching from cigarettes to ZYN reduces the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.
That’s not marketing. That’s a regulatory finding. And while Health Canada hasn’t issued an equivalent ruling, the science doesn’t stop at the border. If you’re a Canadian smoker who has been on the fence about making the switch, this decision is as close to official validation as the pouch category has ever received.
Important context: The FDA is clear that completely quitting all nicotine products remains the best outcome for health. Nicotine is addictive regardless of delivery method. The modified risk designation is specifically for adult smokers who switch completely from cigarettes — not for non-smokers or people who haven’t previously used nicotine. If you don’t currently smoke or use nicotine, pouches are not recommended.
Frequently Asked Questions
No. The FDA explicitly states there is no safe tobacco product. What the FDA authorized is a specific modified risk claim — that using ZYN instead of cigarettes reduces the risk of certain diseases. That is not the same as calling the product safe or recommending it to non-smokers.
No — this is a US FDA decision. Health Canada has not issued equivalent authorization, and Canadian retailers cannot make modified risk marketing claims. ZYN remains legal to purchase and use in Canada for adults 19+ regardless of this ruling.
Twenty products across ten flavours (Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint, Wintergreen) in both 3mg and 6mg strengths. These are all standard ZYN slim pouches.
Yes — ZYN is legally available for purchase in Canada for adults 19+. It can be found through various online Canadian retailers.
That’s a personal health decision best made with your doctor. What the FDA’s ruling confirms is that the science supports a meaningful risk reduction for adult smokers who switch completely. If you’re curious about nicotine pouches as an alternative, our Beginner’s Guide and quitting smoking guide are good starting points.
Swedish Match can apply to renew the MRTP orders before they expire. The FDA will review ongoing surveillance data, including any new evidence on youth uptake or population health impact, before deciding whether to renew or modify the authorization.
Explore Nicotine Pouches at ThePouchVault
Curious about making the switch from cigarettes? Browse our full selection of nicotine pouches — White Fox, Zolt, Pablo, and more — shipped next-day from Fergus, Ontario.
Use code WELCOME10 for 10% off your first order.
⚠️ This post is for informational purposes only. The FDA’s Modified Risk Tobacco Product authorization applies in the United States only and does not constitute Health Canada authorization or approval. Nicotine pouches contain nicotine, which is addictive. For adult nicotine consumers 19+ only. Not intended for non-nicotine users, persons under 19, pregnant or breastfeeding women, or those with heart conditions. If you are considering switching from cigarettes, consult your healthcare provider. ThePouchVault does not make health claims about any product sold on this site.